Toronto Dominion Bank Makes New Investment in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Toronto Dominion Bank acquired a new stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 3,173,258 shares of the company's stock, valued at approximately $35,001,000. Toronto Dominion Bank owned 5.99% of Stoke Therapeutics as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. KLP Kapitalforvaltning AS purchased a new position in Stoke Therapeutics during the fourth quarter valued at approximately $63,000. Teacher Retirement System of Texas purchased a new position in Stoke Therapeutics in the fourth quarter worth $113,000. China Universal Asset Management Co. Ltd. purchased a new position in Stoke Therapeutics in the fourth quarter worth $124,000. Tower Research Capital LLC TRC grew its holdings in Stoke Therapeutics by 70.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company's stock worth $132,000 after purchasing an additional 4,918 shares during the last quarter. Finally, Invesco Ltd. purchased a new position in Stoke Therapeutics in the fourth quarter worth $133,000.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on STOK shares. HC Wainwright cut their price target on shares of Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Cantor Fitzgerald raised shares of Stoke Therapeutics to a "strong-buy" rating in a report on Wednesday, May 14th. Needham & Company LLC reaffirmed a "buy" rating and issued a $22.00 price target on shares of Stoke Therapeutics in a report on Wednesday, April 9th. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $24.00 price target on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $23.20.

Insider Transactions at Stoke Therapeutics

In related news, Director Edward M. Md Kaye sold 10,382 shares of the business's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $90,011.94. Following the completion of the transaction, the director now directly owns 148,253 shares in the company, valued at $1,285,353.51. The trade was a 6.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Barry Ticho sold 3,884 shares of the business's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $33,674.28. Following the transaction, the insider now owns 63,962 shares of the company's stock, valued at $554,550.54. This represents a 5.72% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 16,532 shares of company stock worth $143,332. Company insiders own 11.30% of the company's stock.

Stoke Therapeutics Trading Down 1.2%

Shares of NASDAQ:STOK traded down $0.12 on Friday, hitting $9.61. 375,650 shares of the company were exchanged, compared to its average volume of 707,725. Stoke Therapeutics, Inc. has a 1-year low of $5.35 and a 1-year high of $17.58. The stock's 50 day moving average price is $8.39 and its 200 day moving average price is $9.73. The firm has a market capitalization of $524.68 million, a P/E ratio of -4.58 and a beta of 1.20.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its quarterly earnings data on Monday, March 24th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The business had revenue of $22.61 million during the quarter, compared to the consensus estimate of $4.20 million. On average, equities analysts predict that Stoke Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.